Viking achieves 'maintenance trifecta' as GLP-1/GIP dual agonist exceeds expectations

Viking Therapeutics’ VK2735 met Truist’s “best-case scenario,” with robust weight loss that was largely maintained when patients transitioned to less frequent dosing. Viking’s stock popped more than 30% on Tuesday.